Solv Multi-Pass Hemodialysis System In-Center Clinical Study

Recruiting now · Not applicable

Conditions studied: End Stage Renal Disease

In brief

Solv In-Center clinical study is a pre-market, prospective, multicenter, single arm, open-label clinical study. The patient population will include patients with kidney failure or insufficiency requiring hemodialysis and/or ultrafiltration. Eligibility will be open to incident dialysis patients and patients currently receiving HD in an in-center environment. All vascular access types including AV-fistula, AV-graft, and tunneled hemodialysis catheters.

Key facts

Study ID

NCT07216885

Run by

Mozarc Medical US LLC

People needed

46

Starts

2026-01-13

Expected to finish

2026-07-01

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects able and willing to give Informed Consent and interested to participate in the study
• Subject aged 18 years or older
• Subjects meets one of the following three conditions:
• End stage renal disease (ESRD) patients who have been adequately treated with maintenance HD and deemed stable, according to the investigator, for at least three months
• Incident end stage renal disease (ESRD) patients who have been prescribed HD therapy
• Subjects on peritoneal dialysis who require conversion to hemodialysis, according to the investigator
• Subjects who have adequate access, capable of providing a blood flow rate of at least 300 mL/min
• Subject understands the nature of the procedures and the requirements of the study protocol
• Subject is willing and able to comply with the protocol requirements and return to the treatment center for all required treatments and clinical evaluations

You may not qualify if…

• Subjects with baseline dry weight of ≤ 60 kg or ≥ 110 kg
• Subjects with a documented history of non-compliance to scheduled hemodialysis sessions or clinic visits
• Subjects who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to peritoneal dialysis (PD) within the next two months or who require single needle dialysis therapy
• Subjects with unstable electrolytes or acid base balance, in the opinion of the investigator
• Subjects with any major surgery or major adverse cardiac event within 3 months of screening
• Subjects with hemodynamic instability, defined as repeated hypo/hypertension, in the past 30 days from screening
• Subjects with active or ongoing infection, in the opinion of the Investigator
• Subjects with known Hepatitis B, C or HIV infection
• Subject with documented coagulation disorders, active or bleeding risk or who is intolerant to heparin
• Subjects who are currently participating or have previously participated in another interventional clinical trial in the past 4 weeks from screening
• Subjects with any comorbidities possibly conflicting with the study purpose or procedures, in the opinion of the Investigator
• Subjects who are pregnant or lactating or any patient with a childbearing potential who refuses to use medically acceptable means of contraception
• Subjects with an active, malignant disease and whose life expectancy is < 6 months, in the opinion of the investigator
• Subjects with a hemoglobin < 9 gm/dl in the past 30 days from screening
• Subjects with significant intradialytic hypotension in 30 days from screening
• Subjects with shock within 30 days from screening
• Subjects with active seizures in the last 6 months from screening
• Subjects with history of hemolytic anemia or thrombocytopenia
• Subjects with vascular access dysfunction (switching ports (reverse lines or catheter replacement) in 30 days prior to screening, multiple tPA (tissue plasminogen activator) administrations) or patient who has had a thrombectomy procedure within 30 days prior to screening
• Subjects with a documented history of congestive heart failure with symptoms consistent with NYHA Class III or IV, according to the investigator, or documented severe left ventricular dysfunction
• Subjects with fluid overload due to intractable ascites secondary to liver cirrhosis
• Subjects with active, life-threatening rheumatologic disease

Where it is running

• Carolina Nephrology — Greenville, South Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.